Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toby M Maher

Showing results (271-280 of 392) with videos related to

Pageof 40
Sort By:
Biorxiv : the Preprint Server for Biology|June 10, 2024
Association between mosaic loss of chromosome Y and pulmonary fibrosis susceptibility and severityDapeng Wang, Niran Hadad, Samuel Moss, et al.
The New England Journal of Medicine|May 19, 2025
Nerandomilast in Patients with Idiopathic Pulmonary FibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
Trials|April 30, 2017
Ambulatory oxygen in fibrotic lung disease (AmbOx): study protocol for a randomised controlled trialDina Visca, Vicky Tsipouri, Letizia Mori, et al.
American Journal of Respiratory and Critical Care Medicine|June 30, 2017
Differential Expression of VEGF-A<sub>xxx</sub> Isoforms Is Critical for Development of Pulmonary FibrosisShaney L Barratt, Thomas Blythe, Caroline Jarrett, et al.
The American Journal of Surgical Pathology|November 16, 2011
Diffuse cystic lung disease of unexplained cause with coexistent small airway disease: a possible causal relationship?Camilla Rowan, David M Hansell, Elisabetta Renzoni, et al.
The Lancet. Respiratory Medicine|February 8, 2018
Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?Paul J Wolters, Timothy S Blackwell, Oliver Eickelberg, et al.
American Journal of Respiratory and Critical Care Medicine|September 4, 2014
The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosisPhillip L Molyneaux, Michael J Cox, Saffron A G Willis-Owen, et al.
BMC Pulmonary Medicine|December 5, 2025
Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER™-ON)Wim A Wuyts, Luca Richeldi, Shervin Assassi, et al.
The Lancet. Respiratory Medicine|October 7, 2022
Home monitoring in interstitial lung diseasesMarlies S Wijsenbeek, Catharina C Moor, Kerri A Johannson, et al.
Thorax|June 26, 2020
Interaction between the promoter <i>MUC5B</i> polymorphism and mucin expression: is there a difference according to ILD subtype?Carmel J Stock, Caterina Conti, Ángeles Montero-Fernandez, et al.
Pageof 40

Showing results (271-280 of 392) with videos related to

Sort By:
Pageof 40
Biorxiv : the Preprint Server for Biology|June 10, 2024
Association between mosaic loss of chromosome Y and pulmonary fibrosis susceptibility and severityDapeng Wang, Niran Hadad, Samuel Moss, et al.
The New England Journal of Medicine|May 19, 2025
Nerandomilast in Patients with Idiopathic Pulmonary FibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
Trials|April 30, 2017
Ambulatory oxygen in fibrotic lung disease (AmbOx): study protocol for a randomised controlled trialDina Visca, Vicky Tsipouri, Letizia Mori, et al.
American Journal of Respiratory and Critical Care Medicine|June 30, 2017
Differential Expression of VEGF-A<sub>xxx</sub> Isoforms Is Critical for Development of Pulmonary FibrosisShaney L Barratt, Thomas Blythe, Caroline Jarrett, et al.
The American Journal of Surgical Pathology|November 16, 2011
Diffuse cystic lung disease of unexplained cause with coexistent small airway disease: a possible causal relationship?Camilla Rowan, David M Hansell, Elisabetta Renzoni, et al.
The Lancet. Respiratory Medicine|February 8, 2018
Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?Paul J Wolters, Timothy S Blackwell, Oliver Eickelberg, et al.
American Journal of Respiratory and Critical Care Medicine|September 4, 2014
The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosisPhillip L Molyneaux, Michael J Cox, Saffron A G Willis-Owen, et al.
BMC Pulmonary Medicine|December 5, 2025
Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER™-ON)Wim A Wuyts, Luca Richeldi, Shervin Assassi, et al.
The Lancet. Respiratory Medicine|October 7, 2022
Home monitoring in interstitial lung diseasesMarlies S Wijsenbeek, Catharina C Moor, Kerri A Johannson, et al.
Thorax|June 26, 2020
Interaction between the promoter <i>MUC5B</i> polymorphism and mucin expression: is there a difference according to ILD subtype?Carmel J Stock, Caterina Conti, Ángeles Montero-Fernandez, et al.
Pageof 40